Celecoxib and Cardiovascular Risk

被引：0
|
作者：
Kayyali, Andrea
机构：
来源：
AMERICAN JOURNAL OF NURSING | 2009年 / 109卷 / 03期
关键词：
D O I：
10.1097/01.NAJ.0000346923.59875.c9
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
引用
收藏
页码：29 / 29
页数：1
相关论文
共 50 条
  • [31] Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level
    Varas-Lorenzo, C.
    Maguire, A.
    Castellsague, J.
    Perez-Gutthann, S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S243 - S243
  • [32] ROFECOXIB, BUT NOT CELECOXIB, INCREASES THE RISK OF THROMBOEMBOLIC CARDIOVASCULAR EVENTS IN YOUNG ADULTS - A NATIONWIDE REGISTRY BASED STUDY
    Gudbjornsson, Bjorn
    Thorsteinsson, Sigurdur
    Sigvaldason, Helgi
    Einarsdottir, Rannveip
    Johannsson, Magnus
    Zoega, Helga
    Ilalldorsson, Matthias
    Thorgeirsson, Gudmunur
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2010, 39 : 30 - 30
  • [33] Assessment of the effects of rofecoxib, celecoxib and naproxen on blood pressure and cardiovascular risk: A retrospective chart review study
    Brown, RR
    Olmon, MA
    Estoup, MW
    VALUE IN HEALTH, 2006, 9 (03) : A122 - A122
  • [34] Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level
    Varas-Lorenzo, Cristina
    Maguire, Andrew
    Castellsague, Jordi
    Perez-Gutthann, Susana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (04) : 366 - 376
  • [35] Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials - The cross trial safety analysis
    Solomon, Scott D.
    Wittes, Janet
    Finn, Peter V.
    Fowler, Robert
    Viner, Jaye
    Bertagnolli, Monica M.
    Arber, Nadir
    Levin, Bernard
    Meinert, Curtis L.
    Martin, Barbara
    Pater, Joseph L.
    Goss, Paul E.
    Lance, Peter
    Obara, Stefanie
    Chew, Emily Y.
    Kim, Jonghyeon
    Arndt, Gretchen
    Hawk, Ernest
    CIRCULATION, 2008, 117 (16) : 2104 - 2113
  • [36] Celecoxib lowers risk of recurrent adenomas
    不详
    GERIATRICS, 2006, 61 (11) : 9 - 9
  • [37] Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis REPLY
    Nissen, Steven E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (14): : 1390 - 1390
  • [38] Celecoxib and rofecoxib: risk of GI bleeding
    Reactions Weekly, 2001, 882 (1) : 2 - 2
  • [39] Celecoxib: increased risk of myocardial infarction
    Reactions Weekly, 2006, 1092 (1) : 4 - 4
  • [40] Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults—a nationwide registry-based study
    Bjorn Gudbjornsson
    Sigurdur B. Thorsteinsson
    Helgi Sigvaldason
    Rannveig Einarsdottir
    Magnus Johannsson
    Helga Zoega
    Matthias Halldorsson
    Gudmundur Thorgeirsson
    European Journal of Clinical Pharmacology, 2010, 66 : 619 - 625
12345